Conference Call and Webcast to be Held Wednesday, August 9, 2017, at 4:30 p.m. Eastern Time
BEDMINSTER, NJ / ACCESSWIRE / August 4, 2017 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on
developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease,
announced today that it will issue its financial results for the second quarter and six months ended June 30, 2017, after the
market close on Wednesday, August 9, 2017.
CorMedix CEO, Khoso Baluch, will host a conference call and webcast on Wednesday, August 9, 2017, at 4:30 PM Eastern Time to
discuss recent corporate developments and financial results.
- Dial-In (Toll-Free): 888-567-1603 - International Dial-In:
862-255-5347
The live audio webcast will be accessible via the Events section of the CorMedix website. There will not be live Q&A. To
submit a question by email to be answered on the call, please contact CorMedix@tiberend.com.
A replay of the teleconference will be available until 11:59 p.m. on August 16, 2017.
- Replay Number: 877-481-4010 -
Conference ID: 19772
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel,
non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of
central venous catheters. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute
significantly to increased morbidity and mortality. Neutrolin is currently in a Phase 3 clinical trial in patients undergoing
chronic hemodialysis via a central venous catheter. The Company is working on the design of a planned second Phase 3 clinical
trial, which, if approved, would be subject to sufficient resources. Neutrolin has FDA Fast Track status and is designated as a
Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows
for five additional years of QIDP market exclusivity upon U.S. approval. It is already a CE Marked product in Europe and other
territories. For more information, visit: www.cormedix.com.
For Investors & Media:
Tiberend Strategic Advisors, Inc. Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664 Janine McCargo:
jmccargo@tiberend.com; (646) 604-5150
SOURCE: CorMedix Inc.
